Orally administered dosage forms of GABA analog prodrugs having reduced toxicity
US6833140B2 · kind B2 · utility
16Cited by
54References
29Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 11, 2002 |
| Grant date | Dec 21, 2004 |
| Priority date | — |
| Expiry date | Feb 17, 2023 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07C2601/14
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides an extended release oral dosage form of prodrugs of gabapentin and other GABA analogs, which dosage forms exhibit reduced toxicity. The dosage forms are particularly useful in administering those prodrugs of gabapentin and other GABA analogs that are metabolized to form an aldehyde. The dosage forms of the invention are useful for treating or preventing diseases and/or disorders for which the parent gabapentin or other GABA analog are known to be therapeutically effective.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.